Why the study?
A previous Cochrane review showed considerable uncertainty regarding the benefits and harms of low-dose colchicine for the secondary prevention of cardiovascular events.
Does low-dose colchicine reduce cardiovascular events in adults with a history of stable CVD, MI, or stroke?
Does low-dose colchicine reduce cardiovascular events in adults with a history of stable CVD, MI, or stroke?
Low-dose colchicine provides secondary prevention benefits by reducing myocardial infarction and stroke in patients with cardiovascular disease, though it does not reduce mortality and increases mild gastrointestinal side effects.
Answers are grounded in this paper and cite their sources.
Supports low-dose colchicine for secondary prevention of MI and stroke in stable CVD; reinforces pooled RCT evidence without mortality benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ebrahimi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: